Vistagen Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Vistagen Therapeutics

28/06/2023 22:57

* Vistagen Therapeutics Inc  VTGN.OQ  reported a quarterly
adjusted loss of $1.75​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of $1.50 per share.
    * Revenue rose 351.4% to $175.60 thousand from a year ago;
analysts expected zero. 
    * Vistagen Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.75​.
    * The mean earnings estimate of analysts had fallen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Vistagen Therapeutics Inc shares had fallen by 54.8% this
quarter and lost 45.3% so far this year.
    * The company reported a quarterly loss of $12.23 million.
    * Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data June
28 at 09:57 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.50          -1.75          Missed
 Dec. 31 2022      -2.10          -1.50          Beat
 Sep. 30 2022      -2.00          -2.40          Missed
 Jun. 30 2022      -2.25          -3.00          Missed